Three heart medications combined significantly lower the chance of death, according to a study.

The chance of dying from a second heart attack is reduced by 33% when three cardiac medications are combined into one "polypill," according to new research, which demonstrates that convenience is crucial when it comes to adhering to a treatment regimen.

Because of better adherence to this streamlined approach with a straightforward polypill, the SECURE study's findings demonstrate for the first time that the polypill, which contains aspirin, ramipril (an ACE inhibitor), and atorvastatin (Lipitor), reduces recurrent cardiovascular events among patients who have recovered from a prior heart attack.According to recent studies, taking three cardiac medications together in one "polypill" reduces the chance of dying from a second heart attack by 33%.

He serves as the medical center's chief physician and the director of Mount Sinai Heart in New York City.

Patients are often given three distinct medications following a heart attack: an antiplatelet agent (like aspirin), ramipril or another blood pressure medication, and a cholesterol-lowering medication, such as a statin. The researchers found that less than 50% of patients really take their drugs as directed.

"Within an acute incident, such as myocardial infarction [tissue death], the majority of patients initially adhere to treatment, but after the first few months, adherence decreases. Our intention was to make a difference right away, thus the majority of research participants started taking a straightforward polypill within the first week of suffering a heart attack "said Fuster.

His team randomly allocated approximately 2,500 men and women who experienced a heart attack to receive the new medication (Trinomia) or usual care for the research. The participants were 76 years old, on average.

Researchers discovered that people on Trinomia had a 24% lower overall risk of having a heart attack, stroke, dying from cardiovascular disease, or needing a treatment to clear clogged coronary arteries than patients receiving standard therapy during the course of a three-year follow-up.Over the course of a three-year follow-up, researchers found that participants on Trinomia had a 24% lower overall chance of suffering a heart attack, a stroke, passing away from cardiovascular illness, or needing treatment to unclog clogged coronary arteries than patients getting standard therapy.

Trinomia reduced the risk of dying from cardiovascular disease by 33%, which is even more astonishing, according to the researchers. In comparison to patients taking three medications, individuals utilizing Trinomia were also more likely to stick to their prescription schedule.

Fuster stated in a hospital news release that "the SECURE research findings imply that the polypill could become a key element of strategies to avoid repeated cardiovascular events in patients who have suffered a heart attack." This strategy "has the potential to lower the risk of recurrent cardiovascular disease and death on a worldwide scale by simplifying therapy and enhancing adherence."

The U.S. Food and Drug Administration has not yet approved the polypill used in the study, according to The New York Times, but Fuster said the startling findings would soon be submitted to the organization in an effort to obtain permission.The results were released simultaneously in the New England Journal of Medicine and the European Society of Cardiology Congress on Friday in Barcelona.

Dr. Thomas Wang, chair of the department of internal medicine at UT Southwestern Medical Center, who authored an editorial accompanying the study, told the Times that combination medicines are simpler for both doctors and patients, and the facts are quite obvious - it translates into a benefit. It is simpler to take one medication than several, and it is simpler to take them once daily rather than several times.

According to new research, combining three cardiac drugs into one "polypill" reduces the risk of dying from a second heart attack by 33%, proving the importance of ease in maintaining a treatment program.